HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GENFLEET-B

33.920

+1.1803.60%

Volume:1.41M

Turnover:47.08M

Market Cap:13.03B

PE:-5.59

High:34.480

Open:33.280

Low:31.820

Close:32.740

52wk High:52.900

52wk Low:19.600

Shares:384.00M

HK Float Shares:352.00M

Volume Ratio:1.12

T/O Rate:0.40%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-6.070

ROE:--

ROA:-12.49%

PB:6.15

PE(LYR):-5.59

PS:85.69

Loading ...

Overview Company News Filings

GenFleet Therapeutics FY 2025: Revenue Climbs 24% While Fair-Value Charges Deepen Net Loss; Cash Reserves Surpass RMB 2.07 Billion

Bulletin Express

GenFleet Therapeutics Updates Audit Committee Charter to Strengthen Governance Framework

Bulletin Express

Genfleet Therapeutics (Shanghai) Inc - FY Loss RMB1.79 Bln

THOMSON REUTERS

GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million

Genfleet KRAS G12C inhibitor fulzerasib added to China’s national drug reimbursement list

Wellington Management Increases Stake in GENFLEET-B by 3.82 Million Shares at HK$25.5 Each

GENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting

GenFleet Therapeutics to present preclinical RAS-pathway data at AACR annual meeting

Wellington Management Group LLP Increases Stake in GENFLEET-B by 2.524 Million Shares

GENFLEET-B (02595) Schedules 24 Mar 2026 Board Meeting to Approve FY2025 Results and Final Dividend Proposal

Bulletin Express

GenFleet Therapeutics to hold board meeting to approve annual results and consider final dividend

GENFLEET-B Shares Surge Over 11% on Inclusion in Southbound Trading and Anticipated GFH375 Data Release

GENFLEET-B (02595) Announces Inclusion in Stock Connect Program from March 9, 2026

Bulletin Express

GenFleet Therapeutics Joins Hang Seng Index SeriesGenFleet Therapeutics (Shanghai) Inc. said it will be included in the Hang Seng Index Series from March 9, 2026, including the Hang Seng Composite Index, the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Drug Index

GENFLEET-B (02595) Announces Monthly Securities Movement Update for February 2026

Bulletin Express

GenFleet Therapeutics' GFH375 Granted Breakthrough Designation in China for Lung Cancer

MT Newswires Live

BRIEF-GenFleet Therapeutics (Shanghai) Says GFH375 Granted First Breakthrough Therapy Designation In China

GenFleet Therapeutics (Shanghai) Inc. (2595) Announces Breakthrough Therapy Designation for KRAS G12D Inhibitor in China

Bulletin Express

GENFLEET-B's GFH375 Receives Breakthrough Therapy Designation in China for KRAS G12D-Mutant NSCLC

China CDE Grants GenFleet’s GFH375 Breakthrough Therapy Designation for KRAS G12D NSCLC

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02595/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"GENFLEET-B","latestPrice":33.92,"timestamp":1787299688005,"preClose":32.74,"halted":0,"volume":1410877,"delay":0,"changeRate":0.036041539401343914,"floatShares":352000000,"shares":384000000,"eps":-6.07,"marketStatus":"Not Yet Opened","change":1.18,"latestTime":"08-21 16:08:08","open":33.28,"high":34.48,"low":31.82,"amount":47083422,"amplitude":0.081246,"askPrice":33.92,"askSize":200,"bidPrice":33.74,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-5.174,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":32.74,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":1.122130761325567,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":352000000,"roa":"-12.49%","roe":"--","lyrEps":-6.07,"volumeRatio":1.122130761325567,"shares":384000000,"dividePrice":0,"high":34.48,"amplitude":0.081246,"preClose":32.74,"low":31.82,"week52Low":19.6,"pbRate":"6.15","psRate":"85.69","week52High":52.9,"institutionHeld":0,"latestPrice":33.92,"eps":-6.07,"divideRate":0,"volume":1410877,"delay":0,"ttmEps":-5.174,"open":33.28,"prevYearClose":23.78,"prevWeekClose":30.84,"prevMonthClose":27.74,"prevQuarterClose":29.44,"fiveDayClose":30.84,"twentyDayClose":34.82,"sixtyDayClose":33.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[{"date":"2026-08-21","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787275800000,"name":null,"time":"","dateTimestamp":1787241600000,"actualEps":null},{"date":"2026-03-24","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774315800000,"name":null,"time":"","dateTimestamp":1774281600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1785513600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2026-08-21","current":-6.555856,"percent":0.73991,"low":-19.62221,"twenty":-10.771121,"median":-9.6954,"eighty":-7.255608,"high":-5.69787,"avg":-9.583629,"sd":2.661362,"marketCap":12562836089},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-21","current":-10.329745,"twenty":-18.396816,"median":-10.725216,"eighty":-10.005136,"marketCap":10481375629},{"date":"2025-11-28","current":-10.423287,"twenty":-18.142029,"median":-10.678396,"eighty":-10.044836,"marketCap":10614707615},{"date":"2025-12-05","current":-10.100425,"twenty":-16.087956,"median":-10.631034,"eighty":-10.044836,"marketCap":10303599646},{"date":"2025-12-12","current":-10.212238,"twenty":-13.008301,"median":-10.584309,"eighty":-10.020393,"marketCap":10436931633},{"date":"2025-12-19","current":-9.790532,"twenty":-12.136764,"median":-10.450758,"eighty":-9.957409,"marketCap":10029528340},{"date":"2025-12-24","current":-8.945585,"twenty":-11.809112,"median":-10.416014,"eighty":-9.900509,"marketCap":9192499756},{"date":"2026-01-02","current":-8.020182,"twenty":-11.73453,"median":-10.320373,"eighty":-9.861601,"marketCap":8273990514},{"date":"2026-01-09","current":-11.588563,"twenty":-11.683046,"median":-10.309663,"eighty":-9.776189,"marketCap":11985064146},{"date":"2026-01-16","current":-11.693807,"twenty":-11.67863,"median":-10.369243,"eighty":-9.793132,"marketCap":12133210798},{"date":"2026-01-23","current":-10.361602,"twenty":-11.605818,"median":-10.329745,"eighty":-9.783265,"marketCap":10740632270},{"date":"2026-01-30","current":-10.919089,"twenty":-11.483053,"median":-10.385171,"eighty":-9.793132,"marketCap":11370255541},{"date":"2026-02-06","current":-11.146899,"twenty":-11.598147,"median":-10.450758,"eighty":-9.8258,"marketCap":11636919514},{"date":"2026-02-13","current":-10.659945,"twenty":-11.483053,"median":-10.58187,"eighty":-9.869606,"marketCap":11192479558},{"date":"2026-02-20","current":-10.145441,"twenty":-11.446311,"median":-10.573435,"eighty":-9.881527,"marketCap":10636929613},{"date":"2026-02-27","current":-9.574146,"twenty":-11.38719,"median":-10.509847,"eighty":-9.836956,"marketCap":10148045662},{"date":"2026-03-06","current":-8.841756,"twenty":-11.29428,"median":-10.416014,"eighty":-9.744297,"marketCap":9296202413},{"date":"2026-03-13","current":-10.316011,"twenty":-11.38719,"median":-10.450758,"eighty":-9.761464,"marketCap":10896186254},{"date":"2026-03-20","current":-10.186272,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"marketCap":10718410272},{"date":"2026-03-27","current":-5.945762,"twenty":-11.270982,"median":-10.329745,"eighty":-9.723416,"marketCap":12081359470},{"date":"2026-04-02","current":-6.621163,"twenty":-11.205287,"median":-10.312136,"eighty":-9.574146,"marketCap":13518381995},{"date":"2026-04-10","current":-7.067323,"twenty":-11.18954,"median":-10.310332,"eighty":-9.547859,"marketCap":14540593893},{"date":"2026-04-17","current":-8.194366,"twenty":-11.170082,"median":-10.271344,"eighty":-9.114302,"marketCap":16866496330},{"date":"2026-04-24","current":-11.736244,"twenty":-11.170082,"median":-10.248784,"eighty":-8.950161,"marketCap":18318333519},{"date":"2026-04-30","current":-10.233962,"twenty":-11.173069,"median":-10.230093,"eighty":-8.995356,"marketCap":15977616418},{"date":"2026-05-08","current":-9.881779,"twenty":-11.158327,"median":-10.186272,"eighty":-9.095725,"marketCap":15481325134},{"date":"2026-05-15","current":-8.422278,"twenty":-11.148553,"median":-10.161068,"eighty":-8.948635,"marketCap":13229496023},{"date":"2026-05-22","current":-7.916926,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"marketCap":12407282105},{"date":"2026-05-29","current":-8.035507,"twenty":-11.019944,"median":-10.082937,"eighty":-8.624127,"marketCap":12636909415},{"date":"2026-06-05","current":-6.909175,"twenty":-10.994143,"median":-10.039967,"eighty":-8.441141,"marketCap":10881371589},{"date":"2026-06-12","current":-6.584396,"twenty":-10.981505,"median":-9.989391,"eighty":-8.291507,"marketCap":10362858307},{"date":"2026-06-18","current":-6.718884,"twenty":-10.969649,"median":-9.941921,"eighty":-8.193596,"marketCap":10599892950},{"date":"2026-06-26","current":-5.732708,"twenty":-10.937065,"median":-9.927249,"eighty":-8.035507,"marketCap":8999909109},{"date":"2026-07-03","current":-7.180567,"twenty":-10.922684,"median":-9.900616,"eighty":-7.915515,"marketCap":11281367549},{"date":"2026-07-10","current":-9.054005,"twenty":-10.894174,"median":-9.893411,"eighty":-7.915515,"marketCap":14207263926},{"date":"2026-07-17","current":-8.396292,"twenty":-10.887172,"median":-9.884317,"eighty":-7.956496,"marketCap":13222088691},{"date":"2026-07-24","current":-8.187485,"twenty":-10.884642,"median":-9.862553,"eighty":-8.009423,"marketCap":12896166056},{"date":"2026-07-31","current":-6.510345,"twenty":-10.870773,"median":-9.833804,"eighty":-7.907869,"marketCap":10273970316},{"date":"2026-08-07","current":-7.003679,"twenty":-10.846908,"median":-9.792157,"eighty":-7.575355,"marketCap":11073962237},{"date":"2026-08-14","current":-7.214728,"twenty":-10.805358,"median":-9.754197,"eighty":-7.296139,"marketCap":11422106869},{"date":"2026-08-21","current":-7.917767,"twenty":-10.771121,"median":-9.6954,"eighty":-7.255608,"marketCap":12562836089}],"updateTime":1787501679994},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1193863533","title":"GenFleet Therapeutics FY 2025: Revenue Climbs 24% While Fair-Value Charges Deepen Net Loss; Cash Reserves Surpass RMB 2.07 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1193863533","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193863533?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:41","pubTimestamp":1774395716,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. released FY 2025 results showing revenue of RMB 130.27 million, a 24.45% increase from RMB 104.70 million in 2024. Growth was driven primarily by licensing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123632597","title":"GenFleet Therapeutics Updates Audit Committee Charter to Strengthen Governance Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1123632597","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123632597?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:41","pubTimestamp":1774395705,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. released a revised version of its Audit Committee Terms of Reference, adopted on 24 March 2026, aiming to fortify board-level oversight, enhance transparency and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622011274","title":"Genfleet Therapeutics (Shanghai) Inc - FY Loss RMB1.79 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2622011274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622011274?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:32","pubTimestamp":1774395139,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C16L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622011788","title":"GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622011788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622011788?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:31","pubTimestamp":1774395095,"startTime":"0","endTime":"0","summary":"GenFleet published an annual results announcement for the year ended Dec. 31, 2025.Revenue rose 24.42% to RMB130.3 million, driven primarily by the GFH375 collaboration and out-licensing arrangement with Verastem.Loss for the year was RMB1.8 billion, while adjusted loss  narrowed 9.3% to RMB226.5 million.Research and development costs fell 15.01% to RMB282.3 million, mainly due to lower termination and patent licensing fees recorded in 2024.Cash and bank balances were RMB2.1 billion as of Dec. 31, 2025, and management said it expects to generate more operating cash flow through commercialization of fulzerasib and additional third-party collaborations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8wv7nJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM","BK4139","BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622001120","title":"Genfleet KRAS G12C inhibitor fulzerasib added to China’s national drug reimbursement list","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001120","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001120?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:31","pubTimestamp":1774395082,"startTime":"0","endTime":"0","summary":"Genfleet reported that its KRAS G12C inhibitor fulzerasib became the company’s first marketed product in mainland China and was later approved for sale in Macau.The company said fulzerasib was added to China’s national reimbursement drug list, with coverage scheduled to take effect in 2026.Genfleet stated that it is also advancing multiple RAS-targeted programs, including a KRAS G12D candidate that it expects to support broader pipeline partnering and future commercialization planning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 24, 2026, and is solel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL9VqqrB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163864908","title":"Wellington Management Increases Stake in GENFLEET-B by 3.82 Million Shares at HK$25.5 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1163864908","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163864908?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:22","pubTimestamp":1774264934,"startTime":"0","endTime":"0","summary":"On March 19, Wellington Management Group LLP purchased an additional 3.82 million shares of GENFLEET-B (02595) at HK$25.5 per share, totaling approximately HK$97.50 million. Following this...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161","BK1515","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114020244","title":"GENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1114020244","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114020244?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:38","pubTimestamp":1774013908,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) announced that it will present preclinical research data for three product candidates during the poster session at the 2026 AACR Annual Meeting. The products are GFH276 (a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161","BK1574","BK1515","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620773130","title":"GenFleet Therapeutics to present preclinical RAS-pathway data at AACR annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620773130","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620773130?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:32","pubTimestamp":1774013534,"startTime":"0","endTime":"0","summary":"GenFleet will present preclinical research data on three RAS pathway-targeted therapies at the 2026 AACR Annual Meeting in San Diego, running April 17-22, 2026.Poster presentations are scheduled for April 19, 2026 and April 21, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8MBKjN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151151476","title":"Wellington Management Group LLP Increases Stake in GENFLEET-B by 2.524 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1151151476","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151151476?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:56","pubTimestamp":1773921373,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, Wellington Management Group LLP increased its holdings in GENFLEET-B (02595) by 2.524 million shares on March 17. The transaction was...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","02595","BK1515","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116262730","title":"GENFLEET-B (02595) Schedules 24 Mar 2026 Board Meeting to Approve FY2025 Results and Final Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=1116262730","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116262730?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:22","pubTimestamp":1773267756,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 02595), a joint-stock company incorporated in the PRC, has announced that its board of directors will convene on Tuesday, 24 March 2026. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618790989","title":"GenFleet Therapeutics to hold board meeting to approve annual results and consider final dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2618790989","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618790989?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:07","pubTimestamp":1773266852,"startTime":"0","endTime":"0","summary":"Genfleet will hold a board meeting on March 24, 2026 to consider and approve its annual results for the year ended December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL49d1SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164081911","title":"GENFLEET-B Shares Surge Over 11% on Inclusion in Southbound Trading and Anticipated GFH375 Data Release","url":"https://stock-news.laohu8.com/highlight/detail?id=1164081911","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164081911?lang=en_us&edition=fundamental","pubTime":"2026-03-09 10:10","pubTimestamp":1773022239,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) saw its shares rise more than 11%. At the time of writing, the stock was up 9.96% to HK$27.6, with a turnover of HK$40.0633 million. On the news front, on March 9, GENFLEET-B...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK1574","BK1515","09939","BK4588","VT","02595","159938","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105349362","title":"GENFLEET-B (02595) Announces Inclusion in Stock Connect Program from March 9, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1105349362","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105349362?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:02","pubTimestamp":1773014568,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. (GENFLEET-B, 02595) announced that, according to notices from the Shanghai Stock Exchange and the Shenzhen Stock Exchange, its shares will be included in the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618692639","title":"GenFleet Therapeutics Joins Hang Seng Index SeriesGenFleet Therapeutics (Shanghai) Inc. said it will be included in the Hang Seng Index Series from March 9, 2026, including the Hang Seng Composite Index, the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Drug Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2618692639","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618692639?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:01","pubTimestamp":1773014483,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics Joins Hang Seng Index Series GenFleet Therapeutics  Inc. said it will be included in the Hang Seng Index Series from March 9, 2026, including the Hang Seng Composite Index, the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Drug Index. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL5SLsQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104829936","title":"GENFLEET-B (02595) Announces Monthly Securities Movement Update for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1104829936","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104829936?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:39","pubTimestamp":1772703588,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. (GENFLEET-B, stock code: 02595) published its monthly return for the period ended 28 February 2026, detailing the status of both its Hong Kong-listed and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616066748","title":"GenFleet Therapeutics' GFH375 Granted Breakthrough Designation in China for Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616066748","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616066748?lang=en_us&edition=fundamental","pubTime":"2026-03-02 10:47","pubTimestamp":1772419655,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics   said GFH375 was granted the breakthrough therapy designation in China as a treatment for a type of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.The company is studying the medicine in patients with KRAS G12D-mutant non-small cell lung cancer patients who have received at least one prior systemic therapy.The company expects to announce data from ongoing studies of the medicine at global academic events this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","02595","BK4539","BK1161","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616080398","title":"BRIEF-GenFleet Therapeutics (Shanghai) Says GFH375 Granted First Breakthrough Therapy Designation In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2616080398","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616080398?lang=en_us&edition=fundamental","pubTime":"2026-03-02 09:27","pubTimestamp":1772414861,"startTime":"0","endTime":"0","summary":"BRIEF-GenFleet Therapeutics  Says GFH375 Granted First Breakthrough Therapy Designation In ChinaMarch 2  - GenFleet Therapeutics  Inc 2595.HK:GFH375 GRANTED FIRST BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR A-KRAS G12D INHIBITORFurther company coverage: 2595.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZO04A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148484961","title":"GenFleet Therapeutics (Shanghai) Inc. (2595) Announces Breakthrough Therapy Designation for KRAS G12D Inhibitor in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1148484961","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148484961?lang=en_us&edition=fundamental","pubTime":"2026-03-02 09:21","pubTimestamp":1772414516,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. (GenFleet, 2595) reported that its oral KRAS G12D (ON/OFF) inhibitor GFH375 received Breakthrough Therapy Designation from the Center for Drug Evaluation of the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160117931","title":"GENFLEET-B's GFH375 Receives Breakthrough Therapy Designation in China for KRAS G12D-Mutant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1160117931","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160117931?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:08","pubTimestamp":1772410107,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) announced that its oral KRAS G12D (ON/OFF) inhibitor, GFH375, has been included in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","09939","159938","02595","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616779048","title":"China CDE Grants GenFleet’s GFH375 Breakthrough Therapy Designation for KRAS G12D NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2616779048","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616779048?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:02","pubTimestamp":1772409741,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics  Inc. said the Center for Drug Evaluation of China’s National Medical Products Administration granted Breakthrough Therapy Designation to its oral KRAS G12D inhibitor GFH375 for treating KRAS G12D-mutant non-small cell lung cancer patients who have received at least one prior systemic therapy. The company said the designation was supported by Phase I/II data from the GFH375X1101 study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL9sSv42:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":101,"code":"91000000","status":"200"}]}}